Jingjing Qu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Glycemic Control

Small Cell Lung Cancer

Top Venues

Therapeutic advances in medical oncology

Journal of oncology

Cancer communications (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Jingjing Qu, Yuekang Li, Binggen Wu, Qian Shen, Lijun Chen, Wenjia Sun, Bo Wang, Lixiong Ying, Li Wu, Hong Zhou, Jianya Zhou, Jianying Zhou
CD161 + CD127 + CD8 + T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus. Oncoimmunology 13 (1) (2024)
Jingjing Qu, Yuekang Li, Binggen Wu, Qian Shen, Lijun Chen, Wenjia Sun, Bo Wang, Lixiong Ying, Li Wu, Hong Zhou, Jianya Zhou, Jianying Zhou
CD161 + CD127 + CD8 + T cell subsets can predict the efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer with diabetes mellitus. Oncoimmunology 13 (1) (2024)
Jingjing Qu, Farhin Shaheed Kalyani, Qian Shen, Guangdie Yang, Tianli Cheng, Li Liu, Jianya Zhou, Jian-Ying Zhou
Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study. Journal of oncology 2022 (2022)
Jingjing Qu, Quanhui Mei, Li Liu, Tianli Cheng, Peng Wang, Lijun Chen, Jianying Zhou
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Therapeutic advances in medical oncology 13 (2021)
Jingjing Qu, Farhin Shaheed Kalyani, Li Liu, Tianli Cheng, Lijun Chen
Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer communications (London, England) (2021)